Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: A pilot phase II trial

Qianting He; Shuojin Huang; Dongxiao Tang; Congyuan Cao; Wanhang Zhou; Rongsong Ling; Jie Chen; Bokai Yun; Xin Zheng; Yanchen Li; Anxun Wang; Demeng Chen

doi:10.1002/cac2.70006

Cancer Communications ›› 2025, Vol. 45 ›› Issue (5) : 632 -636. DOI: 10.1002/cac2.70006

LETTER TO THE JOURNAL

Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: A pilot phase II trial

Author information +

History +

PDF

Cite this article

Download citation ▾

Qianting He, Shuojin Huang, Dongxiao Tang, Congyuan Cao, Wanhang Zhou, Rongsong Ling, Jie Chen, Bokai Yun, Xin Zheng, Yanchen Li, Anxun Wang, Demeng Chen. Neoadjuvant chemotherapy plus anlotinib in the treatment of resectable head and neck squamous cell carcinoma: A pilot phase II trial. Cancer Communications, 2025, 45(5): 632-636 DOI:10.1002/cac2.70006

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Mody, MD, Rocco, JW, Yom, SS, Haddad, RI, Saba, NF. Head and neck cancer. Lancet. 2021; 398(10318), 2289-99.

[2]	Shen, G, Zheng, F, Ren, D, Du, F, Dong, Q, Wang, Z, et al. Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018; 11(1), 120.

[3]	Huang, Z, Su, Q, Li, W, Ren, H, Huang, H, Wang, A. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma. J Genet Genomics. 2021; 48(7), 582-94.

[4]	Li, S, Cao, C, Huang, Z, Tang, D, Chen, J, Wang, A, et al. SOD2 confers anlotinib resistance via regulation of mitochondrial damage in OSCC. Oral Dis. 2024; 30(2), 281-91.

[5]	Moncada, R, Barkley, D, Wagner, F, Chiodin, M, Devlin, JC, Baron, M, et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat Biotechnol. 2020; 38(3), 333-42.

[6]	Puram, SV, Tirosh, I, Parikh, AS, Patel, AP, Yizhak, K, Gillespie, S, et al. Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer. Cell. 2017; 171(7), 1611-24. e24.

[7]	Greenwald, AC, Darnell, NG, Hoefflin, R, Simkin, D, Mount, CW, Gonzalez Castro, LN, et al. Integrative spatial analysis reveals a multi-layered organization of glioblastoma. Cell. 2024; 187(10), 2485-501. e26.

[8]	Kim, SH, Singh, SV. The FoxQ1 transcription factor is a novel regulator of electron transport chain complex I subunits in human breast cancer cells. Mol Carcinog. 2022; 61(3), 372-81.

[9]	Cardoso, AP, Pinto, ML, Castro, F, Costa, AM, Marques-Magalhaes, A, Canha-Borges, A, et al. The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment. Cytokine Growth Factor Rev. 2021; 60, 107-19.

[10]	Chen, J, Yao, Y, Gong, C, Yu, F, Su, S, Chen, J, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011; 19(4), 541-55.